Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study

Rahul N Khurana, Louis K Chang, Alok S Bansal, James D Palmer, Chengqing Wu, Mark R Wieland, Rahul N Khurana, Louis K Chang, Alok S Bansal, James D Palmer, Chengqing Wu, Mark R Wieland

Abstract

Background: To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) could continue to extend the macular edema free interval in patients on a treat and extend (TAE) with non-ischemic central retinal vein occlusions (CRVOs) previously treated with ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA) or bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) in the second year.

Methods: Twenty patients with macular edema secondary to non-ischemic CRVOs previously treated with ranibizumab or bevacizumab were prospectively treated with intravitreal aflibercept injection (IAI) using a TAE dosing regimen. Injection frequencies were extended 2 weeks if there were no signs of disease activity on OCT or change in visual acuity. In the second year of the study, patients who have recurrences of macular edema could be re-challenged with a longer treatment interval under the following criterion: absence of any macular edema on three consecutive visits with the same treatment interval.

Results: Twenty patients had an average duration of a CRVO for 22 months (range 7-90) and averaged an anti-VEGF treatment every 42 days (range 28-60 days). The macular edema free interval increased from 38 to 75 days when switched to aflibercept (p = 0.000003) at month 24. There was an average increase of 37 days (median 34 days; range 0-91 days) in the macular edema free interval with aflibercept. At the month 24 visit, 50% (8/16) went > 12 weeks with a macular edema free interval between IAI. There was an improvement in vision (+ 8 ETDRS letters, p = 0.006) and decreased retinal thickness (158 µm, p = 0.00003) with aflibercept treatment at month 24.

Conclusions: The 2-year results of the NEWTON study demonstrated the sustained benefits of a TAE dosing regimen with aflibercept in patients with chronic CRVOs. The visual acuity gains and anatomic improvements observed at year one were maintained through month 24 with less visits and treatments. This may help minimize the treatment burden in patients with recurrent macular edema secondary to non-ischemic CRVO.Trial Registration ClinicalTrials.gov, NCT01870427, Registered June 6, 2013, https://ichgcp.net/clinical-trials-registry/NCT01870427?cond=NEWTON&rank=1.Presented at the RETICON 2017: The Retina Congress with Live Surgery, Chennai, India-April 2017.

Keywords: Aflibercept; Bevacizumab; Central retinal vein occlusion; Chronic; Macular edema; Non-ischemic; Ranibizumab; Treat and extend.

Conflict of interest statement

The following authors have no financial disclosures: Alok S. Bansal, Louis K. Chang, James D. Palmer, and Chengqing Wu.

Figures

Fig. 1
Fig. 1
Macular edema free interval with aflibercept at year 2

References

    1. Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Retina. 1981;1:27–55.
    1. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16:791–799. doi: 10.1038/mt.2008.10.
    1. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(1124–1133):e1.
    1. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119:1024–1032. doi: 10.1016/j.ophtha.2012.01.042.
    1. Haller JA, Bandello F, Belfort R, Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(1134–1146):e3.
    1. Scott IU, VanVeldhuisen PC, Ip MS, et al. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA. 2017;317:2072–2087. doi: 10.1001/jama.2017.4568.
    1. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802–809. doi: 10.1016/j.ophtha.2011.12.005.
    1. Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121:209–219. doi: 10.1016/j.ophtha.2013.08.038.
    1. Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(1414–1420):e1.
    1. Ogura Y, Roider J, Korobelnik JF, et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014;158:1032–1038. doi: 10.1016/j.ajo.2014.07.027.
    1. Khurana RN, Chang LK, Bansal AB, et al. Aflibercept for previously treated macular edema associated with central retinal vein occlusions: 1-year results of the NEWTON Study. Ophthalmol Retina. 2018;2:128–133. doi: 10.1016/j.oret.2017.05.017.
    1. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(429–437):e7.
    1. Larsen M, Waldstein SM, Priglinger S, et al. Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the CRYSTAL study. Ophthalmol Retina. 2018;2:134–142. doi: 10.1016/j.oret.2017.05.016.
    1. American Society of Retina Specialists Preference and Trends (PAT) Survey 2017.
    1. Berg K, Hadzalic E, Gjertsen I, et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results. Ophthalmology. 2016;123:51–59. doi: 10.1016/j.ophtha.2015.09.018.
    1. Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122:2514–2522. doi: 10.1016/j.ophtha.2015.08.009.
    1. Silva R, Berta A, Larsen M, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125:57–65. doi: 10.1016/j.ophtha.2017.07.014.
    1. Scott IU, VanVeldhuisen PC, Ip MS, et al. Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: secondary outcomes from the SCORE2 randomized clinical trial. JAMA Ophthalmol. 2018;136(4):337–345. doi: 10.1001/jamaophthalmol.2017.6843.
    1. Young JM, Wai KM, Silva FQ, et al. Long term outcomes of anti-VEGF therapy in patients with macular edema secondary to retinal vein occlusion. J Vitreoretin Dis. 2017;1:298–304. doi: 10.1177/2474126417721560.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel